key: cord-0945626-7yw8nfis authors: Shirley, Debbie-Ann; Moonah, Shannon title: COVID-19 and Corticosteroids: Unfamiliar but Potentially Fatal Infections That Can Arise following Short-Course Steroid Treatment date: 2021-01-06 journal: Am J Trop Med Hyg DOI: 10.4269/ajtmh.20-1471 sha: 8d50467cdb110862e44bda81dd47e9e433c034bc doc_id: 945626 cord_uid: 7yw8nfis Corticosteroid use is increasing worldwide as recent studies confer survival benefit of corticosteroids in the management of patients with severe COVID-19. Strongyloides and amebic infections are neglected diseases that can progress to catastrophic complications in patients exposed to corticosteroids, even with short treatment courses. To prevent lethal outcomes, clinicians should be aware of the threat these two parasitic infections pose to at-risk patients receiving corticosteroids, especially in the era of COVID-19. Corticosteroids, such as prednisone, hydrocortisone, and dexamethasone, have powerful inhibitory effects on the immune system. Patients with COVID-19 may develop severe inflammatory-mediated disease with acute lung injury and multisystem organ dysfunction. Corticosteroids may improve outcomes in seriously ill COVID-19 patients by attenuating this inappropriate host immune response. [1] [2] [3] [4] [5] Lower 28-day mortality was demonstrated in the large prospective, open-label controlled RECOVERY trial involving 6,425 participants admitted with COVID-19 in those randomized to 6 mg dexamethasone intravenously or orally once daily for up to 10 days than usual care. 3 In those receiving invasive mechanical ventilation, mortality among those treated with dexamethasone was one-third that in those receiving usual care and in those receiving oxygen without mechanical ventilation mortality was reduced by one-fifth. 3 Benefit was also seen in those treated more than 7 days after symptom onset with inflammatory lung damage, but not for those without respiratory support requirement at randomization, suggesting the timing of this intervention within the course of illness may be important. 3 On this basis, the use of corticosteroids, which are relatively inexpensive and readily available medications, has increased worldwide for the treatment of patients with severe COVID-19 disease, as recommended by several health authorities such as the WHO, 4 the NIH, 6 and the Infectious Diseases Society of America. 7 Similarly, evolving observational data also suggest that corticosteroids may be helpful in the management of the multisystem inflammatory syndrome, an uncommon but very serious complication of COVID-19 in children. 1, 8, 9 Despite their utility, corticosteroids can be associated with significant adverse effects, often related to the dose and duration of administration as well as host-specific factors, such as underlying morbidities and concomitant medications. Prolonged systemic use of corticosteroids for more than 2 weeks can be associated with effects such as glaucoma, cataracts, adrenal suppression, hypertension, weight gain, psychologic effects, and gastritis. Shorter term use is better tolerated but can still lead to effects such as hyperglycemia and increased infection risk. Clinicians are likely aware of these common adverse effects of corticosteroids but may be unfamiliar with severe forms of potentially fatal parasitosis that can arise following even very brief courses. Frequently considered infections of endemic low-and middle-income countries, both Strongyloides hyperinfection syndrome and severe amebic colitis, are of global significance because of changing patterns in travel and migration. In the United States, for example, immigrants now account for nearly 15% of the population, with that percentage tripling over the past halfcentury. 10 Social and economic disparities make many of the 47 million immigrants residing in the United States particularly vulnerable to SARS-CoV-2 infection. Here, we bring attention to these potentially fatal infectious risks for COVID-19 patients, especially among at-risk vulnerable populations (Table 1) . Strongyloides stercoralis is a soil-transmitted nematode that infects tens to hundreds of millions of people worldwide. 11 Accurate estimates are limited, but studies suggest prevalence rates as high as 50% in some endemic areas, and 12% or more of immigrant populations may be infected. 11, 12 The U.S. Appalachian region and rural Southern United States as well as the Spanish Mediterranean coast of Southern Europe are notable examples of temperate areas that are also considered endemic. 11, [13] [14] [15] [16] Infection arises when free-living filariform larvae found in human fecally contaminated soil penetrate the skin and migrate to the intestine. 11, 16 Following maturation, adult females lay eggs that become rhabditiform larvae excreted in the feces or develop into infective filariform larvae within the lumen that autoinfect by penetrating the intestinal mucosa, propagating chronic infection. 11 A wide clinical spectrum is seen, ranging from mostly asymptomatic infection to hyperinfection syndrome with dissemination, as the larval form migrates throughout the body. 11 Gramnegative bacteremia and meningitis arise as the larvae carry enteric bacteria with them during migration. 11, 16 Hyperinfection syndrome is associated with high mortality, approaching 90% in disseminated forms. Administration of immunosuppressive medications, such as corticosteroids, is the most commonly identified risk factor for the development of hyperinfection syndrome, which can occur in initially asymptomatic patients. 16, 17 Hyperinfection may manifest as a range of gastrointestinal or pulmonary features, which are challenging to differentiate clinically from those of COVID-19 disease. About two-thirds with chronic infection may have eosinophilia. Stool and lower respiratory samples can be obtained for microscopic examination, but this method generally lacks sufficient sensitivity. 11, 18 Stool PCR performs better than microscopy for diagnosis, but is not widely available. In non-endemic areas, serology helps identify patients with infection but may be less useful in endemic settings where positive serology can also indicate past infection. 11 Strongyloides infection should be suspected in patients with recent or remote travel history to endemic areas or those involved in agricultural work, regardless of time interval, as infection may be lifelong. Recent report of a 68-year-old immigrant from Ecuador with COVID-19 complicated by disseminated strongyloidiasis and polymicrobial septic shock following treatment including methylprednisolone exemplifies the risk. 17 Ivermectin is the drug of choice for targeted treatment once the diagnosis is established. 16 Given that the diagnosis can be challenging, it is reasonable to consider preemptive therapy when strong suspicion exists before corticosteroids. 19 Although ivermectin may inhibit replication of SARS-CoV-2 in vitro, there are no data to support clinical use for COVID-19 treatment. 20 Amebiasis, caused by the protozoan parasite Entamoeba histolytica, infects millions of people worldwide, with multiple areas around the world continuing to observe prevalence rates exceeding 10%. 21 Transmission occurs via ingestion of infective cysts, most commonly by fecally contaminated food or water; however, sexual transmission is increasingly recognized. 21, 22 Following transformation within the gut, the trophozoite stage can invade the intestinal mucosa, leading to inflammatory amebic colitis or disseminate with particular predilection to forming amebic liver abscesses. 21 The highest burden is among those residing in developing countries, although changing patterns in immigration, travel, and sexual transmission are leading to re-emergence of amebiasis in developed settings. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Most cases are asymptomatic with approximately 10% of those infected developing amebic colitis, characterized by diarrhea which may be bloody. 21 Severe forms of amebic colitis, though less common, are associated with high mortality. 32 Colonic involvement may progress to bowel necrosis, perforation, peritonitis, shock, and toxic megacolon. 32 Corticosteroid use, even brief exposure, is a known risk factor for the development of severe amebic colitis, occurring even in initially asymptomatic patients. [32] [33] [34] [35] [36] [37] Patients with diarrhea from amebic colitis are often misdiagnosed as having inflammatory bowel disease and inappropriately treated with steroids, prompting deterioration. 32 Microscopy, which lacks sufficient sensitivity and specificity, is unable to distinguish pathogenic and nonpathogenic amebae, so alternative methods should be used for diagnosis whenever possible. 18, 21, 38, 39 A combination of serology, stool antigen, and/or molecular tests often help establish diagnosis, although serology is more difficult to interpret in endemic settings because it may indicate either past or active infection, and antigen tests may be of low sensitivity, particularly for cyst-containing stool and asymptomatic infection. 38, 40, 41 Stool PCR is highly sensitive but use is limited in resource-poor settings. 21, 42 Those with symptoms should be treated with an amebicidal agent, such as metronidazole, followed by a luminal agent, such as paromomycin. 21, 43 Asymptomatic patients only need to be treated with a luminal agent to prevent future development of colitis and spread to uninfected persons. 21 Strongyloides hyperinfection syndrome and severe amebic colitis are two potentially devastating complications that can arise in patients receiving corticosteroids, independent of dose and duration. Clinicians should consider the possibility of these parasitic infections in at-risk patients, including those with a remote history of travel to endemic areas as these severe complications can arise even years later. Algorithms for screening may be problematic if access to diagnostic testing is not readily available for those at risk; hence, further work is needed to improve the prevalence estimates of these often under-recognized and misdiagnosed infections, as well as to develop and deploy rapid, widely available diagnostics to identify in advance those most likely to benefit from antiparasitic therapy to improve poor outcomes. COVID-19 -lessons learned and questions remaining Early short course corticosteroids in hospitalized patients with COVID-19 Dexamethasone in hospitalized patients with COVID-19 -preliminary report Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial COVID-19 Treatment Guidelines Panel, 2020. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. NIAID-RML. Available at Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19 Multidisciplinary guidance regarding the use of immunomodulatory therapies for acute COVID-19 in pediatric patients Multisystem inflammatory syndrome in children associated with coronavirus disease 2019 in a children's hospital in New York city: patient characteristics and an institutional protocol for evaluation, management, and follow-up Foreign Born: 2019 Current Population Survey Detailed Tables. Table 1.1 Population by Sex, Age, Nativity and US Citizenship Status Strongyloidiasis--an insight into its global prevalence and management Prevalence of strongyloidiasis and schistosomiasis among migrants: a systematic review and meta-analysis Prevalence of Strongyloides stercoralis antibodies among a rural Appalachian population--Kentucky Prevalence of intestinal parasites in a low-income Texas community Human intestinal parasite burden and poor sanitation in rural Alabama Strongyloidiasis: a neglected tropical disease Case report: disseminated strongyloidiasis in a patient with COVID-19 A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the COVID-19 and dexamethasone: a potential strategy to avoid steroid-related strongyloides hyperinfection The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro A review of the global burden, new diagnostics, and current therapeutics for amebiasis Ongoing transmission of Entamoeba histolytica among newly diagnosed people living with HIV in Taiwan Significance of amebiasis: 10 reasons why neglecting amebiasis might come back to bite us in the gut Entamoeba histolytica infection in men who have sex with men Amoebic liver abscess: a neglected tropical disease A possible cluster of sexually transmitted Entamoeba histolytica: genetic analysis of a highly virulent strain A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers Clinical and microscopic predictors of Entamoeba histolytica intestinal infection in travelers and migrants diagnosed with Entamoeba histolytica/dispar infection Imported amoebic liver abscess in France Case report: lower gastrointestinal bleeding due to Entamoeba histolytica detected early by multiplex PCR: case report and review of the laboratory diagnosis of amebiasis Outbreak of intestinal amoebiasis among men who have sex with men, Barcelona (Spain) Fulminant amebic colitis after corticosteroid therapy: a systematic review Multiple colonic and ileal perforations due to unsuspected intestinal amoebiasis-case report and review Approach to amoebic colitis: epidemiological, clinical and diagnostic considerations in a non-endemic context (Barcelona An unexpected colonic mass An autopsy case of fulminant amebic colitis in a patient with a history of rheumatoid arthritis Fatal amebic colitis after high-dose dexamethasone therapy for newly diagnosed multiple myeloma Utility of the rapid antigen detection test E. Histolytica quik chek for the diagnosis of Entamoeba histolytica infection in nonendemic situations New technologies for detection of enteric parasites Two cases of endoscopically diagnosed amebic colitis treated with paromomycin monotherapy Clinical features and gut microbiome of asymptomatic Entamoeba histolytica infection 2017 infectious diseases society of America infectious diarrhea guidelines: a view from the clinical laboratory Antiamoebic drugs for treating amoebic colitis Hygiene has waived the Open Access fee for this article due to the ongoing COVID-19 pandemic. This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.